Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?
Dahdaleh M, Alroughani R, Aljumah M, AlTahan A, Alsharoqi I, Bohlega SA, Daif A, Deleu D, Inshasi J, Karabudak R, Sahraian MA, Taha K, Yammout BI, Zakaria M. Dahdaleh M, et al. Among authors: karabudak r. Int J Neurosci. 2017 Oct;127(10):944-951. doi: 10.1080/00207454.2016.1277424. Epub 2017 Jan 12. Int J Neurosci. 2017. PMID: 28029270 Review.
Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment.
Sen S, Tuncer A, Terzi M, Bunul SD, Ozen-Acar P, Altunrende B, Ozakbas S, Tutuncu M, Uygunoglu U, Akman-Demir G, Karabudak R, Efendi H, Siva A. Sen S, et al. Among authors: karabudak r. Mult Scler Relat Disord. 2023 Nov;79:104949. doi: 10.1016/j.msard.2023.104949. Epub 2023 Aug 25. Mult Scler Relat Disord. 2023. PMID: 37678131
Perivascular PDGFRB+ cells accompany lesion formation and clinical evolution differentially in two different EAE models.
Şekerdağ-Kılıç E, Ulusoy C, Atak D, Özkan E, Gökyüzü AB, Seyaj S, Deniz G, Uçar EA, Budan AS, Zeybel M, Öztop-Çakmak Ö, Vural A, Tuncer A, Karabudak R, Kücükali CI, Tüzün E, Gürsoy-Özdemir Y. Şekerdağ-Kılıç E, et al. Among authors: karabudak r. Mult Scler Relat Disord. 2023 Jan;69:104428. doi: 10.1016/j.msard.2022.104428. Epub 2022 Nov 24. Mult Scler Relat Disord. 2023. PMID: 36450174
A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting.
Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, Freedman M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Miller A; International Working Group for Treatment Optimization in MS. Karussis D, et al. Among authors: karabudak r. Eur J Neurol. 2006 Jan;13(1):61-71. doi: 10.1111/j.1468-1331.2006.01147.x. Eur J Neurol. 2006. PMID: 16420394 Review.
Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis.
Goodin DS, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Karussis D, Miller A, Pakdaman H, Selmaj K, Sharief M; International Working Group for Treatment Optimization in MS. Goodin DS, et al. Among authors: karabudak r. Curr Med Res Opin. 2007 Nov;23(11):2823-32. doi: 10.1185/03007x233007. Curr Med Res Opin. 2007. PMID: 17908370 Review.
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study Group. Giovannoni G, et al. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089960 Free article. Clinical Trial.
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group. Devonshire V, et al. Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Lancet Neurol. 2012. PMID: 22494956 Clinical Trial.
134 results